Tozaro
Tozaro is a company at the intersection of chemistry and biology, focused on transforming the development and manufacture of viral vectors for cell and gene therapy. They leverage 'smart polymers,' which are rationally designed synthetic affinity reagents created through a combination of molecular modeling, machine learning, and chemical synthesis. These smart polymers are tailored to specific viral vectors and applications, offering improved viral vector purification with gentler release conditions and higher yields, as well as enhanced viral vector analytics for rapid, high-throughput quantification. Their technology overcomes the limitations of traditional biological reagents by enabling precise epitope targeting, chemical synthesis for scalability and consistency, and the use of a wider range of building blocks. The company previously operated as MIP Discovery and rebranded to Tozaro after a successful £7M Series A funding round. Their business model is focused on providing these advanced reagents to the cell and gene therapy sector.
Tozaro
Tozaro is a company at the intersection of chemistry and biology, focused on transforming the development and manufacture of viral vectors for cell and gene therapy. They leverage 'smart polymers,' which are rationally designed synthetic affinity reagents created through a combination of molecular modeling, machine learning, and chemical synthesis. These smart polymers are tailored to specific viral vectors and applications, offering improved viral vector purification with gentler release conditions and higher yields, as well as enhanced viral vector analytics for rapid, high-throughput quantification. Their technology overcomes the limitations of traditional biological reagents by enabling precise epitope targeting, chemical synthesis for scalability and consistency, and the use of a wider range of building blocks. The company previously operated as MIP Discovery and rebranded to Tozaro after a successful £7M Series A funding round. Their business model is focused on providing these advanced reagents to the cell and gene therapy sector.